Dynavax Technologies Corporation (DVAX) Stock Rating Reaffirmed by Cowen and Company

Cowen and Company restated their buy rating on shares of Dynavax Technologies Corporation (NASDAQ:DVAX) in a report released on Friday, November 3rd. Cowen and Company currently has a $30.00 price target on the biopharmaceutical company’s stock.

“Dynavax reported a Q3 net loss of $22.1MM and ended the quarter with $192MM in.”,” the firm’s analyst wrote.

Several other brokerages have also issued reports on DVAX. Zacks Investment Research upgraded shares of Dynavax Technologies Corporation from a hold rating to a buy rating and set a $11.00 price target on the stock in a research note on Monday, July 10th. Cantor Fitzgerald initiated coverage on shares of Dynavax Technologies Corporation in a research note on Friday, September 15th. They issued an overweight rating and a $24.00 price target on the stock. Royal Bank Of Canada reissued a buy rating and issued a $26.00 price objective on shares of Dynavax Technologies Corporation in a research report on Friday, September 1st. William Blair reissued an outperform rating on shares of Dynavax Technologies Corporation in a research report on Thursday, July 27th. Finally, ValuEngine raised shares of Dynavax Technologies Corporation from a sell rating to a hold rating in a report on Thursday, September 7th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average target price of $25.17.

Dynavax Technologies Corporation (DVAX) opened at $18.13 on Friday. Dynavax Technologies Corporation has a 52 week low of $3.70 and a 52 week high of $24.45.

Dynavax Technologies Corporation (NASDAQ:DVAX) last posted its earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.53) by $0.15. Dynavax Technologies Corporation had a negative net margin of 1,177.60% and a negative return on equity of 65.97%. The company had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.28 million. During the same period last year, the business posted ($0.90) earnings per share. The business’s revenue for the quarter was down 68.8% compared to the same quarter last year. research analysts forecast that Dynavax Technologies Corporation will post -1.72 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Week Herald and is the sole property of of Week Herald. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://weekherald.com/2017/11/15/cowen-and-company-reaffirms-buy-rating-for-dynavax-technologies-corporation-dvax.html.

A number of hedge funds have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Dynavax Technologies Corporation by 474.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,120 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 5,880 shares during the last quarter. Cubist Systematic Strategies LLC grew its holdings in Dynavax Technologies Corporation by 54.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 3,700 shares during the last quarter. Patriot Financial Group Insurance Agency LLC boosted its stake in shares of Dynavax Technologies Corporation by 16.5% in the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 1,700 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of Dynavax Technologies Corporation by 18.5% in the 2nd quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 1,950 shares during the last quarter. Finally, Wall Street Access Asset Management LLC bought a new stake in shares of Dynavax Technologies Corporation in the 2nd quarter valued at $124,000. Institutional investors and hedge funds own 58.55% of the company’s stock.

About Dynavax Technologies Corporation

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Analyst Recommendations for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply